Paratek Pharma shares surge 6% on late-stage results for antibiotic
Paratek Pharmaceuticals Inc. (PRTK) shares surged as much as 6% in premarket trade Friday after the company said that its antibiotic had positive results in a late-stage clinical trial. The antibiotic, omadacycline, is intended for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in patients with two chronic diseases or conditions. The phase 3 trial compared omadacycline to another antibiotic, linezolid, that's taken twice a day over the course of 7 to 10 days in subsets of patients with chronic kidney disease; high body mass index; diabetes, and a history of intravenous drug use with or without hepatitis C infection. Omadacycline was consistently safe and effective, the company said, and the results suggest no dose adjustments are needed for it in patients with two chronic conditions, called comorbidity. In contrast with linezolid, Paratek said that its omadacycline can be taken once a day; it is also offered in oral and intravenous formulations. The antibiotic has the "potential to address the significant health challenge of antibiotic resistance, even in patients where their comorbid conditions can make it more challenging to treat their infections," Paratek President Dr. Evan Loh said. Paratek shares have surged 8.9% over the last three months, compared with a 5.9% rise in the S&P 500 .
-Emma Court; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
10-06-17 0821ETCopyright (c) 2017 Dow Jones & Company, Inc.